comparison of glp 1 receptor agonists GLP1 vs SGLT2-I in Preventing CKD in T2DM: An Interview – AJKD Blog Mapping the effectiveness and risks

Cholesterol panels typically show improvement by month three

Tirzepatide suppresses palatable food intake by selectively reducing preference for fat in rodents In collaboration with Eli Lilly, we showed that the dual GLP-1/GIP agonist Tirzepatide robustly decreases preference for palatable foods by selectively decreasing lipid consumption

C., Tiuca, R

In January 2026, the company announced a strategic initiative to expand its PharmaPatch microneedle patch platform into select therapeutic peptides

These medications work by slowing digestion, reducing appetite, and improving blood sugar controlall of which can be incredibly beneficial for women over 50